Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,023 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT03563976Recruiting
Imaging study for lung cancer outcomes
This study looks at medical images from people with lung cancer to see how image findings relate to outcomes. It may help doctors better understand which imaging features predict results for patients.
Dallas, TexasAges 18–99 - NCT03582124RecruitingPhase 1/Phase 2
Panitumumab dye to help find lung cancer during surgery
This trial tests a special dye drug (panitumumab-IRDye800) that may help surgeons better see lung cancer areas while operating. If it works, it could improve how well cancer tissue is found and removed during planned lung surgery.
Palo Alto, CaliforniaAges 19 years+ - NCT03647098Recruiting
Lung cancer survival study for adults receiving study treatment
This trial is looking at how well a lung cancer treatment improves survival. It enrolls adults with confirmed lung cancer who can safely take the study medicines and have cancer that can be measured on scans.
Changsha, HunanAges 18 years+ - NCT03702309Recruiting
Banking and testing blood samples to study cancer
This study collects blood samples to “test and store” (bank) information that may help doctors understand cancer in the future. You might be able to join if you’re an adult with confirmed cancer or a higher-than-usual risk for cancer.
Toronto, OntarioAges 18 years+ - NCT03742687Recruiting
Testing a shorter, stronger radiation schedule for lung cancer
This trial studies a different way to deliver radiation to people with locally advanced, non-operable non-small cell lung cancer. It may help by aiming to treat the tumor effectively with a different radiation timing and dose pattern.
AarhusAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT03819296RecruitingPhase 1
Fecal transplant to treat cancer immunotherapy bowel side effects
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
Houston, TexasAges 18 years+ - NCT03948100Recruiting
Yoga coaching for lung or esophageal cancer during radiation
This study tests whether a guided yoga program helps people with lung or esophageal cancer improve strength, daily functioning, and quality of life while they receive radiation therapy. It also involves a family caregiver, to support the patient during treatment.
Houston, TexasAges 18 years+ - NCT03979170Recruiting
Test lung cancer drug response using patient tumor mini-organs
This trial grows “organoids” (mini tumor models) from your lung cancer tissue to see which drug responses are most likely. It may help match future treatments to how your tumor behaves in the lab.
GenevaAges 18 years+ - NCT04790682Recruiting
Liquid blood test to predict first immunotherapy response
This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.
Boulogne-BillancourtAges 18 years+ - NCT06580002RecruitingPhase 2
Can Riluzole Help with Chemo Brain? A Pilot Study
This study tests if a medicine called riluzole (currently used for ALS) can help with 'chemo brain' – memory and thinking problems after cancer treatment. It is for people who feel their mental sharpness has declined after breast cancer therapy, certain chemotherapies, or brain radiation.
Orange, CaliforniaAges 18 years+ - NCT07701733Recruiting
Lung cancer risk study for women who never smoked
This study looks at lung cancer risk in women who have never smoked. It aims to understand why some never-smokers develop lung cancer while others don't.
Basking Ridge, New JerseyAges 40–74 - NCT04063501Recruiting
Study of gut microbes during immunotherapy for lung cancer
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
New York, New YorkAges 18–100 - NCT04067830RecruitingPhase 2
Breathing muscle training before lung surgery to prevent complications
This trial tests whether training your breathing muscles before lung surgery can reduce lung problems after surgery in people with stage I to IIIb lung cancer. It may help improve breathing and lower the chance of post-surgery lung complications.
Buffalo, New YorkAges 18 years+ - NCT04075305Recruiting
Study measuring radiation treatment outcomes with an MR-Linac
This study follows what happens when radiation treatment is guided using an MR-Linac (a special machine that combines MRI imaging with radiation). It may help improve how radiation therapy is planned and assessed, especially for people who can safely have MRI scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04300062Recruiting
Rebiopsy of lung cancer after treatment no longer works
This trial studies patients with lung cancer whose disease has continued to grow despite immunotherapy. It involves taking a new tissue sample (a rebiopsy) to help doctors understand what changed during treatment and guide next steps.
Boulogne-BillancourtAges 18 years+ - NCT04342429Recruiting
Proton radiation study for small cell lung cancer
This study looks at a type of radiation treatment using proton beams (IMPT) for small cell lung cancer. It may help assess whether this approach can safely deliver the planned radiation doses to the chest.
Atlanta, GeorgiaAges 18 years+ - NCT04354064Recruiting
Blood DNA test to see early treatment response in solid tumors
This study looks at circulating tumor DNA, which is tiny bits of DNA found in blood, to help assess how solid tumors are responding early. It uses blood samples from healthy adults who are willing to donate.
St Louis, MissouriAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04676828Recruiting
SPECT-guided radiation to avoid healthy lung in lung cancer
This study tests a special imaging-guided radiation plan that aims to treat lung cancer while reducing radiation to healthy lung tissue. It may help lower lung side effects while keeping the cancer treatment focused on tumor areas.
Sydney, New South WalesAges 18 years+ - NCT04762199RecruitingPhase 1
MRX-2843 with osimertinib for EGFR-mutant lung cancer
This Phase 1 study tests whether combining MRX-2843 with osimertinib can help control advanced lung cancer that has specific EGFR gene changes. It is designed to find the safest dose and check early signs of tumor response.
Atlanta, GeorgiaAges 18 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT04780568RecruitingPhase 1
First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Columbus, OhioAges 18 years+
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,023 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.